OncoAlert
@OncoAlert
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
ID:1109128247789395968
http://www.OncoAlert360.com 22-03-2019 16:22:35
89,2K Tweets
34,5K Followers
157 Following
Follow People
Toni Choueiri, MD
Senior Executive & Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; 2021 Giants of Cancer Award ⚽ lover; 🚲@PanMass, seen on @msnbc @cnn @TODAYshow @GMA
Vivek Subbiah, MD
Chief, Early-Phase Drug Development|@SarahCannonDocs #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
Matteo Lambertini, MD PhD
Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Chair of @myESMO YOC. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.
Stephen V Liu, MD
Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #TexasLung24 #PLCCLive24 #DCLung24 #HereWeGo
ESMO - Eur. Oncology
The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
⚡️ Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis
#KidneyCancer #immunotherapy
JNCI OncoAlert
academic.oup.com/jnci/advance-a…
Daniel Heng with a thorough and systemic overview of the biology and treatment outcomes in translocation RCC. Some initial excellent work from Ziad Bakouny, MD, MSc Srinivas Viswanathan highlight, but clear that additional work is needed in this disease. #IKCSEU24 Kidney Cancer
What do we still need to understand about mechanisms of resistence to ADCs? - with Barbara Pistilli
- Role of the TME: immune and stromal compartment is different across tumor sites
- Co-existing molecular alterations, activated pathways, affecting payload activity and role of…
Proud to have collaborated on this📄w⭐️colleagues Daniel Hall, PhD Lynne I Wagner PhD Dr.SophieLebel 🇨🇦 A/Prof Ben Smith, PhD (he/him) Elyse Park
‼️It's ⏰to integrate evidence-based FCR interventions into existing guidelines to enhance survivorship & alleviate silent suffering doi.org/10.1002/cncr.3…
Great discussion on adjuvant pembro for high-risk RCC at #IKCSEU24 Kidney Cancer by Brian Rini, MD Tom Powles Uromigos - thanks for sharing David Braun !
It is very important to assess benefit-risk ratio for individual patient! Better biomarkers are urgently needed!
Important…
Shaping the future of kidney cancer treatment: Dr. Daniel Heng presents a refined classification system based on therapy response at #IKCSEU24 #Oncology #CancerCare Daniel Heng Kidney Cancer Michael Staehler Salvatore La Rosa Laurence Albiges Cris Dena Battle Ignacio Duran…
At #IKCSEU24 , we're tackling the big question: Why aren't more biomarkers making it to the clinic for RCC?
The search for answers is on. Turajlic Lab @ The Crick #PrecisionMedicine #CancerResearch
Kidney Cancer Michael Staehler Salvatore La Rosa Laurence Albiges Cris Dena Battle Ignacio Duran…
Debate: Adjuvant Therapy for Some or All? in RCC?
Tom Powles for all!
Right time to be in favor of all when you have recent NEJM paper with OS benefit! Toni Choueiri, MD
Kidney Cancer Michael Staehler Salvatore La Rosa Laurence Albiges Cris Dena Battle Ignacio Duran #IKCSEU24 #Oncology …
Just out on npj Journals by Marte Liefaard & team
✅High levels of tumor-infiltrating lymphocytes (TILs) in HER2-positive🧬 #BreastCancer patients undergoing neoadjuvant therapy with trastuzumab and pertuzumab are associated with excellent invasive-disease free survival (IDFS)…
New REVIEW out on Nature Medicine by Anupriya Singhal, Bob T. Li & Eileen M O’Reilly 🇺🇸
Targeting KRAS🧬 in #CancerResearch
Link: nature.com/articles/s4159…
RAS family variants, primarily KRAS, are prevalent hotspot mutations in human cancers with historically limited treatment…
U.S. FDA Approves Adjuvant Alectinib for our patients with ALK+ Early-Stage NSCLC #lcsm OncoAlert ‼️
ALK+ International ALK Positive
fda.gov/drugs/resource…
